How Do Classical Subtypes Correspond to Endotypes in Atopic Dermatitis?
- PMID: 38203432
- PMCID: PMC10779290
- DOI: 10.3390/ijms25010265
How Do Classical Subtypes Correspond to Endotypes in Atopic Dermatitis?
Abstract
Since atopic dermatitis (AD) is a heterogeneous condition, the subtyping of AD is a crucial issue. The classical subtypes of AD are represented by extrinsic and intrinsic subtypes, European-American and Asian subtypes, and adult and pediatric subtypes. While the subtyping of AD was historically conducted based on the phenotype, recent findings on the mechanisms of AD have revealed the importance of the endotype, which can characterize individual patients more accurately. Considering the current development of AD therapies, AD endotyping is a prerequisite for a personalized therapeutic choice. Endotypes of AD can be stratified from different viewpoints, including cytokine expression patterns, allergen properties, epidermal barrier conditions, ceramide variation, the involvement of innate immunity, and serum biomarkers. Among them, the cytokine-based endotype seems to be the most useful one and is categorized into type 2 cytokine (IL-4, IL-13 and IL-31)-high, type 1 cytokine (IFN-γ)-high, and/or type 3 cytokine (IL-22 and IL-17)-high, or mixed subtypes. Recently proposed biomarker endotyping aims at individualized treatment options, although the daily clinical use of endotypes is a future issue. To better understand the endotypes for clinicians, attempts to adjust each of the classical subtypes to endotypes are required. This review will discuss the correspondence of the classical subtypes to the various endotypes that have recently been proposed.
Keywords: atopic dermatitis; endotype; extrinsic type; intrinsic type; phenotype; subtype.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10779290/bin/ijms-25-00265-g001.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10779290/bin/ijms-25-00265-g002.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10779290/bin/ijms-25-00265-g003.gif)
Similar articles
-
Subtypes of atopic dermatitis: From phenotype to endotype.Allergol Int. 2022 Jan;71(1):14-24. doi: 10.1016/j.alit.2021.07.003. Epub 2021 Jul 31. Allergol Int. 2022. PMID: 34344611 Review.
-
Multiple Roles for Cytokines in Atopic Dermatitis: From Pathogenic Mediators to Endotype-Specific Biomarkers to Therapeutic Targets.Int J Mol Sci. 2022 Feb 28;23(5):2684. doi: 10.3390/ijms23052684. Int J Mol Sci. 2022. PMID: 35269828 Free PMC article. Review.
-
Atopic dermatitis endotypes: knowledge for personalized medicine.Curr Opin Allergy Clin Immunol. 2022 Jun 1;22(3):153-159. doi: 10.1097/ACI.0000000000000820. Epub 2022 Feb 11. Curr Opin Allergy Clin Immunol. 2022. PMID: 35152229 Review.
-
Atopic dermatitis endotypes and implications for targeted therapeutics.J Allergy Clin Immunol. 2019 Jan;143(1):1-11. doi: 10.1016/j.jaci.2018.10.032. J Allergy Clin Immunol. 2019. PMID: 30612663 Review.
-
Altered Levels of Sphingosine, Sphinganine and Their Ceramides in Atopic Dermatitis Are Related to Skin Barrier Function, Disease Severity and Local Cytokine Milieu.Int J Mol Sci. 2020 Mar 13;21(6):1958. doi: 10.3390/ijms21061958. Int J Mol Sci. 2020. PMID: 32183011 Free PMC article.
Cited by
-
Biomarkers in Atopic Dermatitis.Dermatol Ther (Heidelb). 2024 Jul;14(7):1729-1738. doi: 10.1007/s13555-024-01193-1. Epub 2024 Jun 14. Dermatol Ther (Heidelb). 2024. PMID: 38874894 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical